PODD in “GLP-1 Eats Everything”
Insulet Corporation
Lower progression to insulin-dependent type 2 diabetes would constrain the incremental addressable market for Insulet's Omnipod pumps, although type 1 demand remains intact.
PODD impact map — “GLP-1 Eats Everything”
How this story travels from the headline to PODD’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading PODD impact map…
Price history, marked with story events
Jul 6, 2026 – Oct 5, 2026 · 66 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BEAR side — Lower progression to insulin-dependent type 2 diabetes would constrain the incremental addressable market for Insulet's Omnipod pumps, although type 1 demand remains intact.
Read the full GLP-1 Eats Everything storyBull side
1 story- Managed Care's Margin Machine Breaks
PODD in “Managed Care's Margin Machine Breaks”
FadingExposure: not rated yetRising utilization, tougher reimbursement and scrutiny of denials are shifting economics from insurers back to care providers.
Expanding diabetes treatment and coverage increase adoption of Insulet's recurring-revenue insulin-delivery systems.
Bear side
1 story- Viewing
PODD in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Lower progression to insulin-dependent type 2 diabetes would constrain the incremental addressable market for Insulet's Omnipod pumps, although type 1 demand remains intact.